Indeed, the exploratory analysis of ATTRACTION-2 concluded that PD-L1 tumor positive score (TPS) was not associated with survival benefit of nivolumab monotherapy in the later line setting for gastric cancer2, while KEYNOTE-061 and KEYNOTE-062 demonstrated the promising clinical utility of PD-L1 CPS in defining gastric cancer patients benefit more from pembrolizumab monotherapy in an earlier clinical setting5,6. This evidence concerns the gene CD274 and gastric cancer.